$ABVC News
Last published 1y ago
- 1y agoABVCABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21GlobeNewswireFREMONT, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and
- 1y agoABVCABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three PartnersGlobeNewswireFREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervous system), and
- 1y agoABVCABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational MilestonesGlobeNewswireABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year.Incremental Payments Received based on Executed Global Licensing Agreements that could provide up to $292
- 2y agoABVCABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic PartnersGlobeNewswireFREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and
- 2y agoABVCABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic AchievementsGlobeNewswire• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents
- 2y agoONCYCADLABVCCTMX+1Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early DetectionPR NewswireUSA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can ...
- 2y agoABVCAiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareGlobeNewswireFREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
- 2y agoABVCABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MGlobeNewswireFREMONT, CA, April 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
- 2y agoABVCABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50MGlobeNewswireFREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
- 2y agoABVCABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MGlobeNewswireFREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
- 2y agoABVCAiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million DollarsGlobeNewswireFREMONT, CA, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in
- 2y agoABVCABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia MagazineGlobeNewswireFREMONT, CA, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in
- 2y agoABVCABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateGlobeNewswireFREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low
- 2y agoABVCABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion DollarsGlobeNewswireFREMONT, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
- 2y agoABVCABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesGlobeNewswireFREMONT, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in
- 2y agoABVCABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)GlobeNewswireFREMONT, CA , Feb. 12, 2024 (GLOBE NEWSWIRE) -- The Company holds a U.S. patent for the same treatment via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical
- 2y agoABVCABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per ShareGlobeNewswireFREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in
- 2y agoABVCABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing FeesGlobeNewswireFREMONT, CA , Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) and its subsidiary BioLite, Inc. ("Company"), a clinical-stage biopharmaceutical company developing
- 2y agoABVCABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical StudyGlobeNewswireFREMONT, CA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in
- 2y agoABVCABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical TrialsGlobeNewswireFREMONT, CA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in
- 2y agoABVCABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion MarketGlobeNewswireFREMONT, CA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
- 2y agoABVCABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200MGlobeNewswireFREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
- 2y agoABVCABVC BioPharma Reports Third Quarter 2023 Financial and Operational ResultsGlobeNewswireFREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high
- 3y agoABVCABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 MillionGlobeNewswireFREMONT, CA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
- 3y agoABVCABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical StudyGlobeNewswireFREMONT, CA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in
- 3y agoABVCABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)GlobeNewswireThe Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical
- 3y agoABVCABVC BioPharma Provides Updates on ADHD Phase IIb Clinical StudyGlobeNewswireFREMONT, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in
- 3y agoABVCABVC Executes Cooperation Agreement for Strategic InvestmentsGlobeNewswireFREMONT, CA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in
- 3y agoABVCABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price RequirementGlobeNewswireFREMONT, CA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
- 3y agoABVCABVC Corporate Update and CEO's Letter to ShareholdersGlobeNewswireFREMONT, CA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
- 3y agoABVCABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park AdministrationGlobeNewswireFREMONT, CA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in oncology/hematology, neurology,
- 3y agoABVCABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net SalesGlobeNewswireFREMONT, CA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, neurology, and
- 3y agoABVCABVC BioPharma Announces Pricing of $1.75 Million Registered Direct OfferingGlobeNewswireFREMONT, CA, July 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
- 3y agoABVCABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic InvestmentsGlobeNewswireFREMONT, CA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in
- 3y agoABVCABVC BioPharma Announces Reverse Stock SplitGlobeNewswireFREMONT, CA, July 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
- 3y agoABVCThe New CEO of ABVC BioPharma Takes Steps to Help Improve Cash EfficiencyGlobeNewswireFREMONT, CA, July 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in
- 3y agoABVCABVC BioPharma, Inc. Announces New CEO as It Targets Further GrowthGlobeNewswireFREMONT, CA, June 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and
- 3y agoABVCABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement ProductionGlobeNewswireFREMONT, CA, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in oncology/hematology, CNS, and
- 3y agoABVCABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSFGlobeNewswireFremont, C, June 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,
- 3y agoABVCABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and CommercializationGlobeNewswireFREMONT, CA, June 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in
- 3y agoABVCABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in AustraliaGlobeNewswireFREMONT, CA, May 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous
- 3y agoABVCABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive DisorderGlobeNewswireFREMONT, CA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and
- 3y agoABVCABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSFGlobeNewswireFremont, CA, April 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and
- 3y agoABVCABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)GlobeNewswireFREMONT, CA, April 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and
- 3y agoABVCABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in ThailandGlobeNewswireFremont, CA, April 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and
- 3y agoABVCABVC BioPharma Announces Fiscal Year 2022 Financial and Operational ResultsGlobeNewswireFREMONT, CA, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low
- 3y agoABVCABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in ThailandPR NewswireFREMONT, Calif., March 20, 2023 /PRNewswire/ -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today
- 3y agoABVCABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and WelfarePR NewswireFREMONT, Calif., March 14, 2023 /PRNewswire/ -- ABVC Biopharma, Inc. ("ABVC" or the "Company") (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in
- 3y agoABVCABVC BioPharma Provides 2023 Pipeline UpdateGlobeNewswireFREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and
- 3y agoABVCABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical TrialsGlobeNewswireFREMONT, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and